Clinical Efficacy of Isatuximab Plus Carfilzomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients.
isatuximab
multiple myeloma
proteasome inhibitors
real life
Journal
European journal of haematology
ISSN: 1600-0609
Titre abrégé: Eur J Haematol
Pays: England
ID NLM: 8703985
Informations de publication
Date de publication:
06 Oct 2024
06 Oct 2024
Historique:
revised:
09
09
2024
received:
23
07
2024
accepted:
18
09
2024
medline:
7
10
2024
pubmed:
7
10
2024
entrez:
6
10
2024
Statut:
aheadofprint
Résumé
Isatuximab, a novel anti-CD38 monoclonal antibody, is approved in combination with carfilzomib and dexamethasone (Isa-Kd) in relapsed/refractory multiple myeloma (RRMM) patients. Because of its recent introduction, real-world efficacy and safety are poorly reported. In this Italian multicenter real-life observational retrospective study, efficacy and safety of the Isa-Kd regimen were evaluated in a cohort of 103 RRMM patients. Overall response rate (ORR) was 85%, with stringent (sCR) or complete response (CR) in 18% of cases and very good partial response (VGPR) in 39%. Median PFS and OS were not reached within the study period, while 1-year PFS and OS were 72% and 77%, respectively. Hematological toxicities were observed in 42% of subjects, and cardiac toxicities occurred in 24% of cases. Moreover, we conducted a subanalysis on patients (N = 69) treated with Isa-Kd after one prior line of therapy, showing an ORR of 88%, with sCR + CR in 20% of subjects, VGPR in 46%, and PR in 22% of patients. In this group, median PFS and OS were not reached, while 1-year PFS and OS were 92% and 95%, respectively. In conclusions, our study confirmed Isa-Kd as an effective treatment option for RRMM with a manageable safety profile even in real-life settings.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 The Author(s). European Journal of Haematology published by John Wiley & Sons Ltd.
Références
S. V. Rajkumar, “Multiple Myeloma: 2024 Update on Diagnosis, Risk‐Stratification, and Management,” American Journal of Hematology 99, no. 9 (2024): 1802–1824, https://doi.org/10.1002/ajh.27422.
S. A. Padala, A. Barsouk, A. Barsouk, et al., “Epidemiology, Staging, and Management of Multiple Myeloma,” Medical Science 9, no. 1 (2021): 3, https://doi.org/10.3390/medsci9010003.
N. Howlader, A. M. Noone, M. Krapcho, et al., SEER Cancer Statistics Review, 1975–2016 (Bethesda: National Cancer Institute, 2019).
M. A. Legarda, M. J. Cejalvo, and J. de la Rubia, “Recent Advances in the Treatment of Patients With Multiple Myeloma,” Cancers (Basel) 12, no. 12 (November 2020): 3576, https://doi.org/10.3390/cancers12123576.
S. Deaglio, K. Mehta, and F. Malavasi, “Human CD38: A (r) Evolutionary Story of Enzymes and Receptors,” Leukemia Research 25, no. 1 (2001): 1–12.
D. De Novellis, R. Fontana, V. Giudice, B. Serio, and C. Selleri, “Innovative Anti‐CD38 and Anti‐BCMA Targeted Therapies in Multiple Myeloma: Mechanisms of Action and Resistance,” International Journal of Molecular Sciences 24, no. 1 (2023): 645, https://doi.org/10.3390/ijms24010645.
A. Gozzetti, S. Ciofini, M. Simoncelli, et al., “Anti CD38 Monoclonal Antibodies for Multiple Myeloma Treatment,” Human Vaccines & Immunotherapeutics 18, no. 5 (November 2022): 2052658, https://doi.org/10.1080/21645515.2022.2052658.
D. De Novellis, R. Fontana, S. Palmieri, et al., “Safety of Subcutaneous Daratumumab in Anti‐CD38 Monoclonal Antibody‐Naïve Patients With Plasma Cell Disorders: A Multicenter Real‐Life Experience,” Targeted Oncology 18 (September 2023): 885–892, https://doi.org/10.1007/s11523‐023‐01001‐4.
F. Bonello, M. D'Agostino, M. Moscvin, C. Cerrato, M. Boccadoro, and F. Gay, “CD38 as an Immunotherapeutic Target in Multiple Myeloma,” Expert Opinion on Biological Therapy 18, no. 12 (2018): 1209–1221, https://doi.org/10.1080/14712598.2018.1544240.
P. Moreau, M. A. Dimopoulos, J. Mikhael, et al., “Isatuximab, Carfilzomib, and Dexamethasone in Relapsed Multiple Myeloma (IKEMA): A Multicentre, Open‐Label, Randomised Phase 3 Trial,” Lancet 397, no. 10292 (June 2021): 2361–2371, https://doi.org/10.1016/S0140‐6736(21)00592‐4.
T. Martin, M. A. Dimopoulos, J. Mikhael, et al., “Isatuximab, Carfilzomib, and Dexamethasone in Patients With Relapsed Multiple Myeloma: Updated Results From IKEMA, a Randomized Phase 3 Study,” Blood Cancer Journal 13, no. 1 (May 2023): 72, https://doi.org/10.1038/s41408‐023‐00797‐8.
S. V. Rajkumar, “Updated Diagnostic Criteria and Staging System for Multiple Myeloma,” American Society of Clinical Oncology Educational Book 36 (May 2016): e418–e423, https://doi.org/10.1200/EDBK_159009.
P. Sonneveld, H. Avet‐Loiseau, S. Lonial, et al., “Treatment of Multiple Myeloma With High‐Risk Cytogenetics: A Consensus of the International Myeloma Working Group,” Blood 127, no. 24 (June 2016): 2955–2962, https://doi.org/10.1182/blood‐2016‐01‐631200.
J. R. J. Dixon, “The International Conference on Harmonization Good Clinical Practice Guideline,” Quality Assurance 6, no. 2 (1998): 65–74, https://doi.org/10.1080/105294199277860.
M. T. Drayson, S. Bowcock, T. Planche, et al., “Levofloxacin Prophylaxis in Patients With Newly Diagnosed Myeloma (TEAMM): A Multicentre, Double‐Blind, Placebo‐Controlled, Randomised, Phase 3 Trial,” Lancet Oncology 20, no. 12 (2019): 1760–1772, https://doi.org/10.1016/S1470‐2045(19)30506‐6.
C. Girmenia, M. Cavo, M. Offidani, et al., “Management of Infectious Complications in Multiple Myeloma Patients: Expert Panel Consensus‐Based Recommendations,” Blood Reviews 34 (2019): 84–94, https://doi.org/10.1016/j.blre.2019.01.001.
S. Kumar, B. Paiva, K. C. Anderson, et al., “International Myeloma Working Group Consensus Criteria for Response and Minimal Residual Disease Assessment in Multiple Myeloma,” Lancet Oncology 17, no. 8 (2016): e328–e346, https://doi.org/10.1016/S1470‐2045(16)30206‐6.
K. Yong, T. Martin, M. A. Dimopoulos, et al., “Isatuximab Plus Carfilzomib‐Dexamethasone Versus Carfilzomib‐Dexamethasone in Patients With Relapsed Multiple Myeloma (IKEMA): Overall Survival Analysis of a Phase 3, Randomised, Controlled Trial,” Lancet Haematol (2024): S235‐2‐3026, https://doi.org/10.1016/S2352‐3026(24)00148‐0.
M. Capra, T. Martin, III, P. Moreau, et al., “Isatuximab Plus Carfilzomib and Dexamethasone Versus Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma Patients With Renal Impairment: Ikema Subgroup Analysis,” Blood 136 (2020): 46–47, https://doi.org/10.1182/blood‐2020‐136415.
F. Gay, W. Roeloffzen, M. A. Dimopoulos, et al., “Results of the Phase III Randomized Iskia Trial: Isatuximab‐Carfilzomib‐Lenalidomide‐Dexamethasone vs Carfilzomib‐Lenalidomide‐Dexamethasone as Pre‐Transplant Induction and Post‐Transplant Consolidation in Newly Diagnosed Multiple Myeloma Patients,” Blood 142, no. Supplement 1 (2023): 4, https://doi.org/10.1182/blood‐2023‐177546.
S. Dwivedi, E. P. Rendón‐Huerta, V. Ortiz‐Navarrete, and L. F. Montaño, “CD38 and Regulation of the Immune Response Cells in Cancer,” Journal of Oncology 2021 (2021): 6630295, https://doi.org/10.1155/2021/6630295.
L. Rao, D. Giannico, P. Leone, et al., “HB‐EGF‐EGFR Signaling in Bone Marrow Endothelial Cells Mediates Angiogenesis Associated With Multiple Myeloma,” Cancers (Basel) 12, no. 1 (2020): 173, https://doi.org/10.3390/cancers12010173.
J. J. Ignatz‐Hoover and J. J. Driscoll, “Therapeutics to Harness the Immune Microenvironment in Multiple Myeloma,” Cancer Drug Resistance (Alhambra, Calif.) 5, no. 3 (2022): 647–661, https://doi.org/10.20517/cdr.2022.23.
O. Perez de Acha, L. Reiman, D. S. Jayabalan, et al., “CD38 Antibody Re‐Treatment in Daratumumab‐Refractory Multiple Myeloma After Time on Other Therapies,” Blood Advances 7, no. 21 (October 2023): 6430–6440, https://doi.org/10.1182/bloodadvances.2023010162.
J. Mikhael, K. Belhadj‐Merzoug, C. Hulin, et al., “A Phase 2 Study of Isatuximab Monotherapy in Patients With Multiple Myeloma Who Are Refractory to Daratumumab,” Blood Cancer Journal 11, no. 5 (October 2021): 89, https://doi.org/10.1038/s41408‐021‐00478‐4.
T. M. Schmidt, R. Fonseca, and S. Z. Usmani, “Chromosome 1q21 Abnormalities in Multiple Myeloma,” Blood Cancer Journal 11, no. 4 (2021): 84, https://doi.org/10.1038/s41408‐021‐00474‐8.
I. Spicka, P. Moreau, T. G. Martin, et al., “Isatuximab Plus Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma Patients With High‐Risk Cytogenetics: IKEMA Subgroup Analysis,” European Journal of Haematology 109, no. 5 (2022): 504–512, https://doi.org/10.1111/ejh.13835.
R. McAvera, J. Quinn, P. Murphy, and S. Glavey, “Genetic Abnormalities in Extramedullary Multiple Myeloma,” International Journal of Molecular Sciences 24, no. 14 (2023): 11259, https://doi.org/10.3390/ijms241411259.
R. Banerjee, K. I. Cicero, S. S. Lee, and A. J. Cowan, “Definers and Drivers of Functional High‐Risk Multiple Myeloma: Insights From Genomic, Transcriptomic, and Immune Profiling,” Frontiers in Oncology 13 (2023): 1240966, https://doi.org/10.3389/fonc.2023.1240966.
M. Ho, S. Zanwar, P. Kapoor, et al., “The Effect of Duration of Lenalidomide Maintenance and Outcomes of Different Salvage Regimens in Patients With Multiple Myeloma (MM),” Blood Cancer Journal 11, no. 9 (September 2021): 158, https://doi.org/10.1038/s41408‐021‐00548‐7.
K. Suzuki and S. Yano, “IMiD‐Free Interval and IMiDs Sequence: Which Strategy Is Better Suited for Lenalidomide‐Refractory Myeloma?,” Lifestyles 13, no. 11 (2023): 2229, https://doi.org/10.3390/life13112229.
Y. X. Zhu, K. M. Kortuem, and A. K. Stewart, “Molecular Mechanism of Action of Immune‐Modulatory Drugs Thalidomide, Lenalidomide and Pomalidomide in Multiple Myeloma,” Leukemia & Lymphoma 54, no. 4 (April 2013): 683–687, https://doi.org/10.3109/10428194.2012.728597.
C. Hulin, M. Beksac, H. J. Goodman, et al., “Antibody Interference and Response Kinetics of Isatuximab Plus Pomalidomide and Dexamethasone in Multiple Myeloma,” Blood Cancer Journal 11, no. 10 (October 2021): 169, https://doi.org/10.1038/s41408‐021‐00562‐9.
R. Fonseca, S. Z. Usmani, M. Mehra, et al., “Frontline Treatment Patterns and Attrition Rates by Subsequent Lines of Therapy in Patients With Newly Diagnosed Multiple Myeloma,” BMC Cancer 20, no. 1 (November 2020): 1087, https://doi.org/10.1186/s12885‐020‐07503‐y.
M. A. Dimopoulos, P. Moreau, E. Terpos, et al., “Multiple Myeloma: EHA‐ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow‐Up†,” Annals of Oncology 32, no. 3 (2021): 309–322, https://doi.org/10.1016/j.annonc.2020.11.014.